2016 Funding Opportunities

Home / Community Blog / 2016 Funding Opportunities

Community Blog

2016 Funding Opportunities

Contributor: Sherry Ward, AltTox

(1) Exploratory/Developmental Bioengineering Research Grants (EBRG): http://grants.nih.gov/grants/guide/pa-files/PA-16-040.html

Application due dates: March 16, July 16, and November 16, 2016

These awards are open to various types of organizations, including small business. The R21 mechanism supports short-term exploratory research projects.

“The purpose of this FOA is to  encourage submission of EBRG applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have high impact; and 3) develop data which can lead to significant future research.”

“Projects may include, but are not limited to, assessing the feasibility of a novel tool for clinical intervention, exploring new approaches to characterizing and modeling complex biological systems, improving and integrating existing technologies to provide a breakthrough in unsolved biomedical problems, or establishing preliminary evidence for a new, perhaps transformative bioengineering approach that challenges accepted paradigms.”

Some research interests by participating NIH organizations are noted in the funding announcement. There are several of particular relevance to the AltTox community:

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): research in building complex 3-dimensional in vitro human musculoskeletal and skin tissue models to study developmental biology, physiology, and disease pathogenesis as well as for drug discovery and toxicity studies
  • National Institute of Dental and Craniofacial Research (NIDCR): multidisciplinary and interdisciplinary biological and bioengineering approaches to advance the regeneration of biocompatible composite tissues that can maintain long-term tissue architecture, anatomical structure, viability and functional inter-tissue interfaces as well as can integrate with native tissues of the host

(2) NIH funding opportunities for US small business:

Notice: HHS issues PHS 2015-2 SBIR and STTR Omnibus Grant Solicitations (NOT-OD-15-101):

  • PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (PA-15-269)
  • PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) (PA-15-270)

Application due dates: January 5, April 5, and September 5, 2016

In additional to the “parent” funding announcements above, there are additional small business funding opportunities to support entrepreneurship training, translation, and test method validation, including the following:

(2A) NIEHS SBIR Phase IIB Awards for Validation and Commercialization of Approaches to Reduce Animal Use in Toxicology Testing: http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-15-016.html

Don’t despair if you were not yet ready for the Nov. 17, 2015 application deadline, as this funding opportunity has the additional application due dates of November 14, 2016 and November 13, 2017.

This funding is available to limited applicants – small businesses with funded SBIR/STTR Phase II awards or contracts completed within the past 24 months

The need for this additional form of funding is explained as follows: “US federal agencies may have additional validation requirements, beyond OECD guidelines, which must be met for acceptance of an alternative test method.”

(2B) SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance (SB1): http://grants.nih.gov/grants/guide/pa-files/PAR-16-026.html

Application due dates: September 5, January 5, and April 5, 2016

“The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy and/or planning for a clinical trial.”

(2C) Innovation Corps (I-Corps™) at NIH Program for NIH and CDC Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp): http://grants.nih.gov/grants/guide/pa-files/PA-16-019.html

Application due dates: December 10, 2015 and March 21, 2016

“The expanded I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to a cohort of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program.

(3) Europe’s EFSA call for proposals: Modelling human variability in toxicokinetic and toxicodynamic processes using Bayesian meta-analysis, physiologically-based modelling and in vitro systems: http://www.efsa.europa.eu/en/art36grants/article36/gpefsascer20101

Proposal due date: Jan 18, 2016

“The purpose of this article 36 project is to further demonstrate the feasibility of developing web-based tools integrating human variability in TK and TD processes for chemical risk assessment by means of Bayesian meta-analysis, physiologically-based modeling and integration of TK parameters generated through in vitro experiments using human cells.”

The proposal has to be submitted by a consortium of at least three eligible organizations. “Eligible” means the applicant and partners must be on this list of competent organizations: http://www.efsa.europa.eu/en/networks/art36.htm

(4) Human Immunology Project Consortium: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-041.html

Application due date: March 16, 2016

Although not specifically focused on alternative methods, data developed from the human systems immunology studies funded by this FOA could someday support new alternative methods for biologics/vaccines:

“This initiative seeks to fund additional immune profiling projects that are focused on the analysis of well-defined and characterized human cohorts utilizing a variety of modern tools appropriate for systems biology analyses, which involve the rigorously controlled, unbiased, and quantitative collection of large data sets that are then integrated to create models of complex molecular and cellular interactions that will provide insights into how the system functions as a whole, and describe various aspects of host immunity in the context of vaccinations, adjuvants and/or microbial infections. Investigators will use new and established comprehensive laboratory and bioinformatics technologies to generate molecular response profiles from primary immune cells and their products obtained from human volunteers within well-characterized cohorts. The new HIPC awardees will join the 2015 awardees and operate as one consortium….”